Moderna’s COVID vaccine given FDA OK
Moderna’s COVID-19 vaccine won backing from a panel of experts who advise U.S. regulators, setting the stage for its shot to be the second vaccine cleared in the U.S. in as many weeks.
Food and Drug Administration advisers voted 20 to 0, with one abstention, on Thursday that the benefits of the vaccine outweigh any risk, giving a boost to efforts to ramp up the U.S. immunization campaign. The effort is initially focusing on health- care workers and seniors who live in long- term care facilities. The FDA could authorize the shot within the next day.
Moderna’s product is based on the same technology as a shot made by Pfizer Inc. and BioNTech SE that was cleared by the FDA last week, and like that vaccine showed a high degree of efficacy in late- stage clinical trials. At Thursday’s advisory meeting, some of the discussion focused on a handful of allergic reactions experienced by people in the U. S. and U.K. who got the Pfizer shot.
In a report ahead of the meeting, FDA staff determined Moderna’s vaccine is 94.1% effective against symptomatic COVID-19. The report listed side effects like headache, fatigue and muscle aches typical of a vaccine.
Side effects seen in the rollout of the shot from Pfizer and BioNTech are leading U. S. regulators to bolster instructions for doctors and those that receive the shot. Pfizer and the U.S. Food and Drug Administration are revising fact sheets handed out with the vaccine, Doran Fink, deputy director of FDA’s division of vaccines and related products applications, said in the advisory panel meeting.
The revisions ref lect guidelines from the Centers for Disease Control and Prevention to monitor patients and ensure facilities have medication on hand to treat rare, but serious, allergic reactions. Two people in Alaska who received the Pfizer-BioNTech vaccine suffered reactions, which have also been seen in a few U.K. vaccine recipients.
“As we continue to evaluate and investigate the data, we will determine whether additional recommendations need to be made,” Fink said in the online panel meeting.
U.K. health officials have warned anyone who has a history of anaphylactic reactions to food, medicine or a vaccine shouldn’t get the Pfizer shot. The FDA hasn’t